However, in this case, as the patient lacked FLT3 mutations and considering the available combinational data on sorafenib and immunotherapy for hepatocellular carcinoma (HCC) sorafenib was deemed the more suitable choice (30, 31). The gene discussed is FLT3; the disease is hepatocellular carcinoma.